VTVT logo

vTv Therapeutics (VTVT) Company Overview

Profile

Full Name:

vTv Therapeutics Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 30, 2015

Indexes:

Not included

Description:

vTv Therapeutics is a biopharmaceutical company focused on developing innovative therapies for chronic diseases. They aim to improve patient outcomes through their research on drug candidates targeting conditions like diabetes and Alzheimer's. Their work combines science and technology to create effective treatments for unmet medical needs.

Events Calendar

Earnings

Next earnings date:

Mar 13, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 13, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 21, 2023

Analyst ratings

Recent major analysts updates

Dec 9, 24 Alliance Global Partners
Buy
Mar 7, 23 HC Wainwright & Co.
Buy
Aug 17, 22 Northland Capital Markets
Outperform
Feb 18, 22 Cantor Fitzgerald
Overweight
Feb 10, 20 HC Wainwright & Co.
Buy
Feb 10, 20 H.C. Wainwright
Buy
May 30, 19 HC Wainwright & Co.
Buy
May 30, 19 H.C. Wainwright
Buy
May 6, 19 Northland Capital Markets
Outperform
Apr 10, 18 Stifel Nicolaus
Hold

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
VTVT
globenewswire.comAugust 8, 2024

Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license effective upon payment of the $20 million upfront fee HIGH POINT, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today reported financial results for the second quarter ended June 30, 2024, and provided an update on recent corporate developments.

Why Is vTv Therapeutics (VTVT) Stock Down 46% Today?
Why Is vTv Therapeutics (VTVT) Stock Down 46% Today?
Why Is vTv Therapeutics (VTVT) Stock Down 46% Today?
VTVT
investorplace.comJuly 29, 2024

VTv Therapeutics (NASDAQ: VTVT ) stock is falling hard on Monday after the Food and Drug Administration (FDA) placed a clinical hold on its cadisegliatin clinical program. According to a news release from the company, that hold includes its TT1 Phase 3 trial in type 1 diabetes.

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
VTVT
globenewswire.comJuly 26, 2024

HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. Cadisegliatin is an oral, liver selective, glucokinase activator that has been well-tolerated in over 500 subjects to date with up to six months of treatment.

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
VTVT
globenewswire.comJune 24, 2024

Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
VTVT
prnewswire.comMay 28, 2024

WESTON, Fla. , May 28, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Cantex's azeliragon, a well-tolerated once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products), will be featured in four abstracts at this year's 2024 ASCO Annual Meeting to be held in Chicago.

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON
CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON
CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON
VTVT
PRNewsWireJune 15, 2023

WESTON, Fla. , June 15, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, today announced that it will present at the MedInvest Oncology Investor Conference being held June 21-22, 2023, in Boston, MA.

FAQ

  • What is the ticker symbol for vTv Therapeutics?
  • Does vTv Therapeutics pay dividends?
  • What sector is vTv Therapeutics in?
  • What industry is vTv Therapeutics in?
  • What country is vTv Therapeutics based in?
  • When did vTv Therapeutics go public?
  • Is vTv Therapeutics in the S&P 500?
  • Is vTv Therapeutics in the NASDAQ 100?
  • Is vTv Therapeutics in the Dow Jones?
  • When was vTv Therapeutics's last earnings report?
  • When does vTv Therapeutics report earnings?
  • Should I buy vTv Therapeutics stock now?

What is the ticker symbol for vTv Therapeutics?

The ticker symbol for vTv Therapeutics is NASDAQ:VTVT

Does vTv Therapeutics pay dividends?

No, vTv Therapeutics does not pay dividends

What sector is vTv Therapeutics in?

vTv Therapeutics is in the Healthcare sector

What industry is vTv Therapeutics in?

vTv Therapeutics is in the Biotechnology industry

What country is vTv Therapeutics based in?

vTv Therapeutics is headquartered in United States

When did vTv Therapeutics go public?

vTv Therapeutics's initial public offering (IPO) was on July 30, 2015

Is vTv Therapeutics in the S&P 500?

No, vTv Therapeutics is not included in the S&P 500 index

Is vTv Therapeutics in the NASDAQ 100?

No, vTv Therapeutics is not included in the NASDAQ 100 index

Is vTv Therapeutics in the Dow Jones?

No, vTv Therapeutics is not included in the Dow Jones index

When was vTv Therapeutics's last earnings report?

vTv Therapeutics's most recent earnings report was on Nov 12, 2024

When does vTv Therapeutics report earnings?

The next expected earnings date for vTv Therapeutics is Mar 13, 2025

Should I buy vTv Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions